A walk through tau therapeutic strategies

Article Article scientifique Revue de la littérature A walk through tau therapeutic strategies eng 2019 author Jadhav Santosh author Avila Jesus author Scholl Michael 519429 author Kovacs Gabor G author Kovari Eniko Veronika 501395 author Skrabana Rostislav author Evans Lewis D author Kontsekova Eva author Malawska Barbara author de Silva Rohan author Buee Luc author Zilka Norbert 22 10.1186/s40478-019-0664-z 30767766 2051-5960 Tau neuronal and glial pathologies drive the clinical presentation of Alzheimer's disease and related human tauopathies. There is a growing body of evidence indicating that pathological tau species can travel from cell to cell and spread the pathology through the brain. Throughout the last decade, physiological and pathological tau have become attractive targets for AD therapies. Several therapeutic approaches have been proposed, including the inhibition of protein kinases or protein-3-O-(N-acetyl-beta-D-glucosaminyl)-L-serine/threonine Nacetylglucosaminyl hydrolase, the inhibition of tau aggregation, active and passive immunotherapies, and tau silencing by antisense oligonucleotides. New tau therapeutics, across the board, have demonstrated the ability to prevent or reduce tau lesions and improve either cognitive or motor impairment in a variety of animal models developing neurofibrillary pathology. The most advanced strategy for the treatment of human tauopathies remains immunotherapy, which has already reached the clinical stage of drug development. Tau vaccines or humanised antibodies target a variety of tau species either in the intracellular or extracellular spaces. Some of them recognise the amino-terminus or carboxy-terminus, while others display binding abilities to the proline-rich area or microtubule binding domains. The main therapeutic foci in existing clinical trials are on Alzheimer's disease, progressive supranuclear palsy and non-fluent primary progressive aphasia. Tau therapy offers a new hope for the treatment of many fatal brain disorders. First efficacy data from clinical trials will be available by the end of this decade. Aggregation Alzheimer's disease Immunotherapy PET imaging Tau vaccines Tauopathies Therapeutic interventions Dewey 616.89 60 Département de psychiatrie 225 false 1221 Neuroimagerie moléculaire en psychiatrie 983 Acta Neuropathologica Communications 7 1 af9211a0-90f9-4a58-a241-475e71ddc566 Article (Published version) Public document(1).pdf 1880131 application/pdf CC BY openAccess Faculté de médecine / Section de médecine clinique / Département de psychiatrie

Title	Published in	Year	Views	Downloads

A walk through tau therapeutic strategies	Acta Neuropathologica Communications	2019	455	1,295
Chapitre 11 LDIP : Faillite et concordat	Poursuite et faillite : Commentaire de la Loi fédérale sur la poursuite pour dettes et la faillite ainsi que des articles 166 à 175 de la Loi fédérale sur le droit international privé	2005	599	1

Archive ouverte UNIGE

Scholl, Michael